ARTICLE | Clinical News
Reminyl galantamine acetylcholinesterase inhibitor and nicotinic receptor modulator regulatory update
March 5, 2001 8:00 AM UTC
The FDA granted marketing approval to SHP and partner Janssen Pharmaceutica Products LP (Beerse, Belgium) for Reminyl to treat mild-to-moderate Alzheimer's disease (AD). Reminyl is approved in Europe,...